The particulars: survodutide · twenty-eight days.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
Why does this happen, and what would falsify the usual explanation?
Moving the day by 28 stretches one interval from 7 days to 35 — one interval, and then it is over. At a seven-day half-life the trough at the end of a normal week sits at 50 per cent of the preceding peak. At the end of a 35-day week it sits at 0.5^(35÷7) = 3.1 per cent: a fall of 46.9 percentage points, once, after which every interval is 7 days again. That is the entire pharmacokinetic content of the change. Whether 46.9 points of trough is worth anything is a question about your own tolerability curve rather than about the molecule. A move of 28 days is longer than the interval itself, which makes it not a shift at all but a missed dose followed by a new schedule — and it should be reasoned about as one. Timing changes are made under supervision; nothing here is medical advice.
Start with the interval since the missed dose, because that single number determines the answer.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Two or more missed weekly doses means considering a lower restarting step.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant arithmetic is that one missed dose of a weekly agent produces a trough about half the usual, which is well inside the normal range.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Stated carefully, to change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.